Drug Combination Details
| General Information of the Combination (ID: C97187) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
|
Nasopharyngeal cancer
[ICD-11: 2B6B]
|
Investigative | [1] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | |||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
|
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [3] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | Drp1-mediated mitochondrial fission | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| BEAS-2B | CVCL_0168 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | A549 non-small cell lung cancer cells (2*106) resuspended in 0.1mL of PBS were injected subcutaneously into athymic (nu/nu) male nude mice (5-6 weeks old). | |||||
| Experimental
Result(s) |
Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
| ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | |||
| A-498 | CVCL_1056 | Renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation. | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | microRNA 301 | Molecule Info | ||
| In-vitro Model | PANC1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Rattus norvegicus | ||
| Experimental
Result(s) |
The levels of miR-301-3p were down-regulated in PANC-1 cells exposed to luteolin, which inhibits the growth of PANC-1 cells and sensitizes cells to TRAIL. | |||||
| Experiment 4 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | CNE-1 | CVCL_6888 | Human nasopharyngeal carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Luteolin sensitizes TRAIL-induced apoptosis through down-regulation of XIAP. | |||||
| Experiment 5 Reporting the Effect of This Combination | [6] | |||||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. | |||||
